Skip to content

Clinical trials

Completed Diabetes Mellitus trials in Germany

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus Status: Completed Country / region: Germany Clear all

421 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
200110
200211
200316
200416
20059
200623
200717
200818
200930
201028
201121
201227
201330
201431
201527
201622
201717
201817
20198
20207
20215
202211
20239
20244
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed421

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S180
AstraZeneca21
Institut fur Diabetes Karlsburg GmbH15
Profil Institut für Stoffwechselforschung GmbH14
Takeda13
Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm12
Eli Lilly and Company9
Forschungsinstitut der Diabetes Akademie Mergentheim9
GlaxoSmithKline8
German Diabetes Center5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus421
Diabetes Mellitus, Type 2165
Diabetes Mellitus, Type 183
Glucose Metabolism Disorders16
Insulin Resistance15
Obesity11
Dyslipidemias10
Hypertension10
Cardiovascular Diseases6
Diabetic Neuropathies6

Trials

Showing 1 to 25 of 421. Each trial links to its page on Pharma Observatory.

321 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.